Drug Interactions between aldesleukin and Omnipaque 180

GENERALLY AVOID: Intrathecal administration of iodinated contrast media may induce seizures. There may be a theoretical risk of increased seizure potential when iodinated contrast agents are used with other substances that can reduce the seizure threshold such as aldesleukin.

MONITOR CLOSELY: An increased incidence (12.6%) of acute, atypical reactions to iodinated contrast media has been observed in patients who have been previously treated with interleukin-2. The cause and mechanism have not been established. Symptoms generally have an onset of 1 to 4 hours and may include nausea, vomiting, diarrhea, fever, chills, rash, pruritus, hypotension, edema, and oliguria. Reactions have typically been reported when patients received iodinated contrast media within 4 weeks after the last dose of interleukin-2, but have also occurred several months after interleukin treatment.

MANAGEMENT: Aldesleukin should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media. Patients should be monitored for adverse reactions during and after the myelography, and symptomatic treatment initiated as clinically appropriate.